

## Foreword

### Elizabeth Yeu, MD

Dr Yeu earned her medical degree through an accelerated and combined undergraduate/medical school programme at the University of Florida College of Medicine. She completed her ophthalmology residency at Rush University Medical Center in Chicago, where she served as Chief Resident (2006–2007). Dr Yeu continued to the Cullen Eye Institute, Baylor College of Medicine, to complete a fellowship in cornea, anterior segment and refractive surgery (2007–2008), where she served as an Assistant Professor after her fellowship training. Dr Yeu joined Virginia Eye Consultants in 2013, is now a partner (since 2014) and continues her commitment to residency training in ophthalmology as an Assistant Professor at the Eastern Virginia Medical School. She was the Medical Director of CVP Physicians Mid-Atlantic (2019–2021) and of the Virginia Surgery Center, and also sits on the Board of Directors for the Virginia Eye Foundation. Dr Yeu provides guidance and governance across several national medical boards and committees, including as an examiner for the American Board of Ophthalmology, Treasurer and Executive Board member of the American Society of Cataract and Refractive Surgery (ASCRS), the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Academy of Ophthalmology (AAO), and the Chair of the AAO Annual Meeting Refractive Surgery Sub-committee. Dr Yeu has authored numerous articles and is a frequent lecturer, nationally and internationally, in the areas of refractive cataract surgery, anterior segment reconstruction, ocular surface disease management and surgical management of astigmatism. She is the Editor-in-Chief of *touchREVIEWS in Ophthalmology* and served as Medical Editor of the digital journal, *Millennial Eye* from 2015 to 2017. Dr Yeu has been voted onto The Ophthalmologist's global Power List five times: in 2015, 2017, 2019, 2020 and 2021. She was awarded the first Clinical Rising Star by the Ophthalmic Innovations Summit (OIS) in 2018, recognized as a Castle Connolly Top Doc 2016–2021 and received their Exceptional Women in Medicine Award in 2017–2018, earned the Best Doctors Award by her peers from 2013 to 2016, awarded the Millennial Eye Award in 2015 and recognized as one of the Top 40 Under 40 by Virginia's Inside Business journal.



Welcome to the latest edition of *touchREVIEWS in Ophthalmology*, which includes a wide range of articles that reflect the rapid pace and broad scope of ophthalmology research. Regrettably, we begin with an obituary. We are sorry to announce the death of one of our valued board members, Professor Emilio Campos.

Starting from the front of the eye, herpes zoster keratitis is a common manifestation of the varicella zoster (shingles) virus, and is associated with numerous complications. Take a look at this thorough review article by Mohammed et al., which discusses the challenges of managing chronic and recurrent zoster keratitis.

The treatment and management of the common sight-threatening disease, keratoconus, have undergone huge advances in recent years. Milliken et al. present a review of current medical and surgical treatment options designed to prevent future ectasia, as well as to reduce refractive error in our challenging patients with irregular astigmatism.

Glaucoma is the leading cause of irreversible blindness worldwide, and it continues to be a major health burden, despite numerous advances. Micro-pulse transscleral laser therapy has recently become an established non-surgical procedure for a range of patients with glaucoma. Töteberg-Harms and Bernardi describe their experience with this procedure and discuss its benefits for glaucoma management during the COVID-19 pandemic.

The management of exudative age-related macular degeneration is a rapidly evolving and fascinating area of intense research. Intravitreal injections of anti-vascular endothelial growth factor have become standard of care in the treatment of neovascular age-related macular degeneration (nAMD). However, treatment frequency is lower in clinical practice than in clinical trials, leading to suboptimal outcomes. Baumal et al. review the port delivery system using ranibizumab, an exciting recent development that could lead to a paradigm shift in the treatment of nAMD.

Our final review covers the common inflammatory aetiology of dry eye disease (DED). Beckman et al. discuss the mechanism of action, efficacy and safety of KPI-121 ophthalmic suspension 0.25%, an ophthalmic nanoparticle suspension of loteprednol etabonate that has recently been approved for the treatment of DED.

*touchREVIEWS in Ophthalmology* would like to take this opportunity to thank all participants in this edition. We would like to thank our contributors and reviewers for providing us with insightful and informative review articles. We are also grateful to all organizations and society partners for their ongoing support, and the members of our editorial board for their continued involvement and advice. We hope that you will find this edition of *touchREVIEWS in Ophthalmology* an enjoyable and informative read. Finally, we wish all our readers a healthy and happy 2022. □